Hepatitis B and hepatitis C which is the major viral infection are threating to people‘s health in China .According to expert estimates, hepatitis B virus carriers accounted for 8% -10% of the total population (about 140 million). The number of hepatitis C patients less than the number of patients with hepatitis B, but it is showing an increasing trend.Patients with chronic hepatitis B and hepatitis C can lead to cirrhosis considerable part or even liver cancer. Therefore, the development of new anti-hepatitis B and hepatitis C drugs (including small molecule compounds, biological drugs and vaccines) is an urgent task.

Our team has many  years of hepatitis B and hepatitis C drug development experience. We can provide for the domestic universities, research institutes and Medicines Co  with vivo and  vitro drug screening and evaluation.

1. The anti-hepatitis B virus drug development

    1.1 vitro cell screening model for HBV viral drugs

    1.1.1 HepG2.2.15 cell model: The model is  HepG2 cells transfected with human whole HBV genome .It can be used to evaluate the inhibitory effect of drugs on HBV viral replication, include:

          a) culture supernatant HBsAg and HBeAg

          b) cell culture supernatant HBV-DNA, HBV-cccDNA, HBV-DNA intracellular

     1.1.2 DHBV infection of primary Sheldrake liver cell model

        The technology used a two-step perfusion DHBV prepared by the legal system of primary infection Shaoxing duck liver cells for anti-HBV drug screening, including cell culture supernatant DHBV-DNA, intracellular DHBV-DNA.

     1.2  vivo anti HBV virus screening evaluation model

      1.2.1 in vivo anti duck hepatitis B virus (DHBV) model

        This method uses Sheldrake with positive DHBV  ( grouped on virus concentration ，8-10 Sheldrake each group).Dosing according to the design of administration route and dose of drugs.Dosing 10 days total. Collect blood at 5,10 and 5 days after stopping dosing.Detecting serum DHBV-DNA level of the  Sheldrakes by fluorescence quantitative PCR .And observing the situation according to pathological liver lesions.Calculating the inhibition rate of DHBV-DNA  and liver lesions ,evaluating drug's effects of  anti-virus and the alleviation of liver damage.

      1.2.2 HBV transgenic mouse model

        This method uses transgenic mouse (grouped on HBV viral concentration). Dosing according to the design of administration route and dose of drugs.Dosing 21 days total，and  stop for 7 days.Collecting blood each 7 days.Detecting serum HBV-DNA and HBV-cccDNA level by fluorescence quantitative PCR.

2. Anti-HCV drugs

       2.1 flavivirus HCV infected cell model simulation: bovine viral diarrhea mucosal virus (BVDV) Analog HCV

        It is very difficult for  HCV particles to develop in vitro. Establishment of HCV RNA replication system can evaluate the  drugs’effect  on HCV replication inhibition.However,  HCV virus particles can not complete a full replication process.So,it is can not be identificated if the effect of anti-HCV drugs work  in the early stages of viral replication cycle or late stage currently. Bovine viral diarrhea - mucosal virus (BVDV) and HCV have many similar places, it is an ideal model of HCV strains.

        Using Non-toxic concentrations of the drug acting on MDCK cells infected with BVDV.BVDV viral load was measured by quantitative PCR method to evaluate the inhibitory effect of drugs on the BVDV replication.

       2.2 HCV NS3 / 4A serine protease inhibitor screening model

        Making synthetic peptide as substrate, using fluorescence resonance energy transfer screening HCV NS3 / 4A serine protease inhibitor.